{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:10:32Z","timestamp":1783091432657,"version":"3.54.6"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12325-023-02669-w","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T12:02:56Z","timestamp":1695384176000},"page":"5090-5101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases"],"prefix":"10.1007","volume":"40","author":[{"given":"Darmendra","family":"Ramcharran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"DeKlotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fakharzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Swerdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Dronavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"3","key":"2669_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40261-018-00745-6","volume":"39","author":"T Yamamoto","year":"2019","unstructured":"Yamamoto T. Clinical characteristics of Japanese patients with palmoplantar pustulosis. Clin Drug Investig. 2019;39(3):241\u201352.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2669_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.13846","volume":"31","author":"M Misiak-Galazka","year":"2017","unstructured":"Misiak-Galazka M, Wolska H, Rudnicka L. What do we know about palmoplantar pustulosis? J Eur Acad Dermatol Venereol. 2017;31(1):38\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2669_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","volume":"98","author":"M Murakami","year":"2020","unstructured":"Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020;98(1):13\u20139.","journal-title":"J Dermatol Sci"},{"issue":"7","key":"2669_CR4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00296-018-4034-0","volume":"38","author":"M Benzaquen","year":"2018","unstructured":"Benzaquen M, Flachaire B, Rouby F, Berbis P, Guis S. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn\u2019s disease-associated spondyloarthropathy. Rheumatol Int. 2018;38(7):1297\u20139.","journal-title":"Rheumatol Int"},{"issue":"3","key":"2669_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","volume":"21","author":"M Misiak-Galazka","year":"2020","unstructured":"Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21(3):355\u201370.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"2669_CR6","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2011.05.038","volume":"67","author":"E Shmidt","year":"2012","unstructured":"Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179-185.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2669_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1): e006450.","journal-title":"BMJ Open"},{"issue":"5","key":"2669_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/bjd.17832","volume":"181","author":"YMF Andersen","year":"2019","unstructured":"Andersen YMF, Augustin M, Petersen J, et al. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Dermatol. 2019;181(5):976\u201382.","journal-title":"Br J Dermatol"},{"key":"2669_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20087","author":"S Lofvendahl","year":"2021","unstructured":"Lofvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of palmoplantar pustulosis in Sweden: a population-based register study. Br J Dermatol. 2021. https:\/\/doi.org\/10.1111\/bjd.20087.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2669_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","volume":"19","author":"JM Overhage","year":"2012","unstructured":"Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54\u201360.","journal-title":"J Am Med Inform Assoc"},{"issue":"3","key":"2669_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jamia\/ocu023","volume":"22","author":"EA Voss","year":"2015","unstructured":"Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553\u201364.","journal-title":"J Am Med Inform Assoc"},{"key":"2669_CR12","unstructured":"Centers for Disease Control. Morbidity Frequency Measures in Principles of Epidemiology in Public Health Practice, Third Edition. Accessed 9 Feb 2022. https:\/\/www.cdc.gov\/csels\/dsepd\/ss1978\/lesson3\/section2.html"},{"key":"2669_CR13","unstructured":"US Food and Drug Administration. FDA Insight: Rare Diseases and Orphan Products. Interview. Updated 12\/01\/2020. Accessed 7 Mar 2022. https:\/\/www.fda.gov\/news-events\/fda-insight\/fda-insight-rare-diseases-and-orphan-products"},{"issue":"5","key":"2669_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232738","volume":"15","author":"C Miyazaki","year":"2020","unstructured":"Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: a claims database study. PLoS One. 2020;15(5): e0232738.","journal-title":"PLoS One"},{"issue":"5","key":"2669_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/03007995.2021.1894108","volume":"37","author":"ML Hanna","year":"2021","unstructured":"Hanna ML, Singer D, Valdecantos WC. Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States. Curr Med Res Opin. 2021;37(5):735\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2669_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"JM Ko","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20(2):100\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"2669_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","volume":"40","author":"AN Collamer","year":"2010","unstructured":"Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233\u201340.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02669-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02669-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T10:43:56Z","timestamp":1697021036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02669-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2669"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02669-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time the research was conducted, Darmendra Ramcharran was an employee of Janssen Research & Development; he is currently an employee of GSK. Bruce Strober served as a consultant (honoraria) and\/or speaker and\/or investigator for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol\u00a0Myers\u00a0Squibb, Cara, Connect Biopharma, CorEvitas Psoriasis Registry, Dermavant, Dermira, Eli Lilly, EPI Health, Evelo Biosciences, Immunic Therapeutics, Incyte, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ono, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, UCB Pharma, Union Therapeutics, Ventyxbio, and vTvt Therapeutics; served as co-Scientific Director (consulting fee) of CorEvitas (formerly Corrona) Psoriasis Registry and Editor-in-Chief (honorarium) of <i>Journal of Psoriasis and Psoriatic Arthritis<\/i>. Kenneth Gordon received research\/grant support from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma, and honoraria for consultation from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, Novartis, and UCB Pharma. Amy Paller has been an investigator for AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, and UCB; a consultant with honorarium for Aegerion Pharma, Azitra, BioCryst, Boehringer\u00a0Ingelheim, Bristol Myers Squibb, Castle Creek, Eli Lilly, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi\/Genzyme, Seanergy, TWI Biotechnology, and UCB; and is on data safety monitoring boards for AbbVie, Abeona, Catawba, Galderma, and InMed. Cynthia DeKlotz, Joel Swerdel, and Jill Hardin are employees of Janssen Research & Development and Steven Fakharzadeh and Ya-Wen Yang are employees of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson; employees may own stock in Johnson & Johnson, of which Janssen is a subsidiary. Sridhar Dronavalli has no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Optum and IBM MarketScan databases used in this study were reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval, as this research project did not involve human subject research. Based on Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor and Welfare, ethics approval and informed consent for the JMDC database were not applicable for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}